Valuation: Avacta Group Plc

Market Cap 340M 447M 394M 363M 636M 42.15B 648M 4.36B 1.69B 20.79B 1.68B 1.64B 72.33B P/E 2025
-6x
P/E 2026 * -10.8x
Enterprise Value 340M 448M 394M 363M 637M 42.19B 649M 4.37B 1.69B 20.81B 1.68B 1.64B 72.4B EV / Sales 2025
37.2x
EV / Sales 2026 * -
Free-Float
98.8%
Yield 2025 *
-
Yield 2026 * -

Last Transcript: Avacta Group Plc

1 day+0.42%
1 week-1.36%
Current month-8.23%
1 month-8.23%
3 months+7.41%
6 months+38.10%
Current year+25.00%
1 week 68.75
Extreme 68.75
75
1 month 66.9
Extreme 66.9
82
Current year 48
Extreme 48
92
1 year 28
Extreme 28
92
3 years 26
Extreme 26
166.98
5 years 26
Extreme 26
189.94
10 years 13
Extreme 13
291.8
Manager TitleAgeSince
Chief Executive Officer 56 2024-03-31
Director of Finance/CFO 51 2025-01-21
Chief Tech/Sci/R&D Officer - 2026-02-08
Director TitleAgeSince
Director/Board Member 60 2020-02-02
Director/Board Member 71 2021-08-16
Director/Board Member 56 2022-03-17
Date Insider Type Main position Quantity % Market Cap.
24-09-01Sell

Chief Financial Officer

500,000 0.1393%
24-09-01Free

Chief Executive Officer

3,600,000 1.0027%
24-09-01Fiscal year

Chief Financial Officer

500,000 0.1393%
Change 5-day change 1-year change 3-year change Capi.($)
+0.42%-1.36%+133.87%-40.57% 446M
-7.92%-4.05%+53.28%+106.11% 57.55B
+8.55%+17.56%+76.80%+82.31% 47.08B
-0.45%-2.18%-14.16%-15.80% 22.92B
+1.28%+5.09%-2.30%+418.34% 22.14B
+4.17%+8.64%+27.72%-14.07% 16.33B
-0.15%+4.15%+27.79%-34.84% 15.97B
+2.98%+0.82%+15.64%+166.21% 12.9B
+5.94%+14.85%+134.05%+296.09% 12.85B
-0.71%+1.98%+78.88%+114.48% 11.84B
Average +1.41%+4.96%+53.16%+107.83% 22B
Weighted average by Cap. +0.62%+5.34%+46.00%+115.36%

Financials

2025 2026 *
Net sales 6.25M 8.23M 7.24M 6.68M 11.71M 776M 11.93M 80.31M 31.11M 383M 30.9M 30.23M 1.33B -
Net income -33.95M -44.7M -39.35M -36.3M -63.61M -4.21B -64.8M -436M -169M -2.08B -168M -164M -7.23B -30.5M -40.16M -35.35M -32.61M -57.14M -3.78B -58.21M -392M -152M -1.87B -151M -147M -6.5B
Net Debt 330K 434K 382K 353K 618K 40.93M 629K 4.24M 1.64M 20.19M 1.63M 1.59M 70.25M 26.93M 35.46M 31.22M 28.8M 50.47M 3.34B 51.41M 346M 134M 1.65B 133M 130M 5.74B
Logo Avacta Group Plc
Avacta Group plc is a United Kingdom-based life sciences company developing peptide drug conjugates (PDC) targeting anti-tumor payloads directly to the tumor. The Company is focused on the development of its proprietary preCISION technology platform. The preCISION platform is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The preCISION platform harnesses this tumor-specific protease to cleave preCISION peptide drug conjugates and preCISION antibody/Affimer drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity. Its lead program, AVA6000, is a clinical-stage asset which is a preCISION-enabled form of doxorubicin. AVA6103, the Company’s second program, is a preCISION-enabled PDC comprised of the preCISION peptide linked to exatecan, the most potent topoisomerase I (topo I) inhibitor in clinical development.
Employees
151
Date Price Change Volume
26-06-24 GBX 72.50 +0.42% 850,895
26-06-23 GBX 72.20 +0.28% 1,327,870
26-06-22 GBX 72.00 -1.37% 1,707,444
26-06-19 GBX 73.00 -0.68% 975,756
26-06-18 GBX 73.50 0.00% 933,085
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.7250GBP
Average target price
0.8233GBP
Spread / Average Target
+13.56%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AVCT Stock